XML 57 R37.htm IDEA: XBRL DOCUMENT

Collaborative and Licensing Arrangements (Tables)

12 Months Ended

Dec. 31, 2024

The following table summarizes total collaboration revenue recognized for the years ended December 31, 2024, 2023 and 2022:


	Year Ended December 31,
	2024	2023	2022
Revenue from Collaborators	$	$	$

Research and development service revenue	—	79,431	46,822
Right to access intellectual property revenue	—	104,477	104,994
Material rights revenue	—	71,980	—
Other	30,695	13,039	9,493
Total	30,695	268,927	161,309

The following table summarizes collaboration revenue recognized in connection with the tislelizumab collaboration and license agreement for the years ended December 31, 2024, 2023 and 2022:


	Year Ended December 31,
	2024	2023	2022
	$	$	$

Research and development service revenue	—	72,278	39,655
Other 1	2,113	5,067	9,493
Total	2,113	77,345	49,148

1 Represents revenue recognized on sale of tislelizumab clinical supply to Novartis in conjunction with the collaboration.

The following table summarizes collaboration revenue recognized in connection with the ociperlimab option, collaboration and license agreement for the years ended December 31, 2024, 2023 and 2022:


	Year Ended December 31,
	2024	2023	2022
	$	$	$
Research and development service revenue	—	7,153	7,167
Right to access intellectual property revenue	—	104,477	104,994
Material rights revenue	—	71,980	—
Other 2	18,259	8,859	—
Total	18,259	192,469	112,161

2 Represents revenue generated under the broad markets marketing and promotion agreement in conjunction with the collaboration.

The table below presents the Company’s net product sales for the years ended December 31, 2024, 2023 and 2022.


	Year Ended December 31,
	2024	2023	2022
	$	$	$
Product revenue - gross	4,786,744	2,718,969	1,438,440
Less: Rebates and sales returns	(1,007,198)	(529,117)	(183,828)
Product revenue - net	3,779,546	2,189,852	1,254,612

The following table disaggregates net product revenue by product for the years ended December 31, 2024, 2023 and 2022.


	Year Ended December 31,
	2024	2023	2022
	$	$	$
BRUKINSA®	2,644,226	1,290,396	564,651
Tislelizumab	620,836	536,620	422,885
XGEVA®	224,403	92,828	63,398
BLINCYTO®	74,331	54,342	36,107
KYPROLIS®	66,171	39,799	13,696
POBEVCY®	53,509	56,547	38,124
REVLIMID®	36,028	76,018	79,049

Other	60,042	43,302	36,702
Total product revenue - net	3,779,546	2,189,852	1,254,612

Schedule of Collaboration Agreements

Amounts recorded related to the Company’s portion of the co-development funding on the pipeline assets for the years ended December 31, 2024, 2023 and 2022 were as follows:


	Year Ended December 31,
	2024	2023	2022
	$	$	$
BeiGene’s portion of the development funding	148,391	108,608	195,357
Less: Amortization of research and development cost share liability	73,226	55,294	96,402
Research and development expense	75,165	53,314	98,955

			As of December 31, 2024
Remaining portion of development funding cap			335,261

As of December 31, 2024 and 2023, the research and development cost share liability recorded in the Company’s balance sheet was as follows:


	As of December 31,
	2024	2023
	$	$
Research and development cost share liability, current portion	111,154	68,004
Research and development cost share liability, non-current portion	54,286	170,662
Total research and development cost share liability	165,440	238,666

Schedule of Amounts and Classification of Reimbursement Expense

The net reimbursement paid under the commercial profit-sharing agreement for in-line product sales is classified in the consolidated statements of operations for the three years ended December 31, 2024 as follows:


	Year Ended December 31,
	2024	2023	2022
	$	$	$
Cost of sales - product	37,150	8,358	5,898
Selling, general and administrative	(83,674)	(60,917)	(54,865)
Research and development	(2,438)	1,688	(1,216)
Total	(48,962)	(50,871)	(50,183)

Schedule of Payments Due to Collaboration Partners

Upfront and milestone payments made under these arrangements for the years ended December 31, 2024, 2023 and 2022 are set forth below. All upfront and development milestones were expensed to research and development expense. All regulatory and commercial milestones were capitalized as intangible assets and are being amortized over the remainder of the respective product patent or the term of the commercialization agreements.


		Year Ended December 31,
		2024	2023	2022
Payments due to collaboration partners	Classification	$	$	$
Upfront payments	Research and development expense	60,027	46,800	68,665
Development milestone payments	Research and development expense	54,000	—	5,500
Regulatory and commercial milestone payments	Intangible asset	—	24,365	—
Total		114,027	71,165	74,165